Surprise pharma inspections uncover 50% failure rate

Add bookmark

The China Food and Drug Administration (CFDA) conducted over 430 pharma inspections last year, which saw over 50% of the drug manufacturers disappoint expectations 

Around 39 unannounced inspections took place in 2016 and 54% of the drug manufacturers involved failed. It was considered whether GMP certificates should be repealed for around 14 of those firms.

Flawed products that belonged to seven firms were ordered for recall. All issues have been rectified in accordance with legislation

The CFDA achieved a five year high for overseas inspections for imported pharmaceuticals. The 49 inspections stretched across 19 countries.

Issues with data integrity had serious repercussions on medicine integrity with some manufacturers.

All issues have now been dealt with, quality control and quality assurance were found to be the dominant problem areas. The production processes used in manufacturing plants were in some instances found to differ from those specified in registration application, major changes had been made without an application.

Ding Jianhua, Director of Department of Drug and Cosmetics Supervision of the CFDA says, "One manufacturer from a European Union country didn't report to the CFDA their major change and even added some APIs, active ingredients to their production, they didn't report their source of materials, we stopped the importation of them.”

He added that foreign manufacturers did follow Chinese regulations, however some smaller companies in developing countries sometimes were not aware of Chinese regulations or forgot about the region’s  requirements.

Around 12 pharma manufacturers passed their GMP certification inspections, of the seven that struggled to pass their certification, issues were again primarily linked to quality control, quality assurance, documentation management followed by equipment deficiencies.  

Quality management systems were a key stumbling point – not operating effectively and failing to meet production and quality requirements for products. The operability of the files was lacking and data wasn’t recorded in some instances.

For some firms inspected process validation was not adequate for all medicines including the cleaning validation for public equipment.

The audits ran by the CFDA included: pre-approval inspections, GMP certification inspections, GMP follow-up inspections, unannounced inspections, overseas inspections, GSP unannounced inspections and inspection observations. These involved around 1270 inspectors. 


Upcoming Events

Cosmetic Compliance New York 2016

October 17 - 19, 2016

MANHATTAN NYC – An Affinia Hotel Collection, New York, NY

Cosmetic Compliance New York 2016

Pharma Traceability November - 2016

November 30 - December 2, 2016

Sheraton Philadelphia University City Hotel, Philadelphia, PA

Pharma Traceability November - 2016

UDIs and Traceability for Medical Devices

15 - 18 May, 2018

Pullman Brussels Centre Midi Hotel, Brussels, Belgium

UDIs and Traceability for Medical Devices

CRISPR: A New Era in Gene Editing

December 5 - 7, 2016

Embassy Suites by Hilton Boston at Logan Airport, Boston, MA

CRISPR: A New Era in Gene Editing

10. Jahreskonferenz Pharma Packaging 2016

29 February - 2 March, 2016

Golden Tulip Berlin - Hotel Hamburg, Berlin, Germany

10. Jahreskonferenz Pharma Packaging 2016

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...